
Rockwell Medical (RMTI) ์ฃผ์
์์ฅ ๊ธฐ์ . 9์ 2026 ๊ธฐ์ค Rockwell Medical์ ์ฃผ๊ฐ, ์ฌ์ ๊ฐ์, ์์๋์ด์ผ ํ ํต์ฌ ์ ๋ณด๋ฅผ ์ ๋ฆฌํ์ต๋๋ค.
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patientโs bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
6๊ฐ์ ์ฑ์ฅ ์ฑ๊ณผ
์ฃผ๊ฐ ์ฑ๊ณผ ์์ฝ
์ ๋๋ฆฌ์คํธ ํ๊ฐ
Analysts suggest buying Rockwell Medical's stock with a target price of $20, indicating significant growth potential.
์ฌ๋ฌด ๊ฑด์ ์ฑ
Rockwell Medical is generating modest revenue and cash flow but has low profit margins.
์ฑ์ ๋ฌด๋ฃ๋ก ๋ค์ด๋ก๋ํ๊ณ ๋ ๋ง์ ์ข ๋ชฉ ๋ณด๊ธฐ
60์ด๋ฉด ์ถฉ๋ถํฉ๋๋ค.
์ Nemo์ ํจ๊ป ํฌ์ํด์ผ ํ ๊น์?
์์๋ฃ ๋ฌด๋ฃ
์ฃผ์, ETF ๋ฑ์ ์์๋ฃ ์์ด ๊ฑฐ๋ํ์ธ์. ์์ต์ ๋ ๋ง์ด ์งํค์ธ์.
์ ๋ขฐํ ์ ์๋ ๊ท์ ๊ธฐ๊ด ์ธ๊ฐ
2015๋ ๋ถํฐ Exinity Group์ ์ผ์์ผ๋ก, ์ ์ธ๊ณ 100๋ง ๋ช ์ด์์ ๊ณ ๊ฐ์๊ฒ ์๋น์ค๋ฅผ ์ ๊ณตํฉ๋๋ค.